EMA Withdrawn: Zontivity (vorapaxar sulfate) — Merck Sharp Dohme Limited

View source ↗

Summary

EU withdrawal of Zontivity (vorapaxar sulfate) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Zontivity (vorapaxar sulfate)

Snippet

Status: Withdrawn. Therapeutic area: Myocardial Infarction. MAH: Merck Sharp Dohme Limited. Decision date: 29/07/2016